Form 4 Filing for Allogene Therapeutics, Inc.

This filing details a transaction by Annie Yoshiyama, SVP, Finance, involving the sale of 9,586 shares of Common Stock of Allogene Therapeutics, Inc. on April 21, 2026. The shares were sold at a weighted average price of $2.31, with the sale ranging from $2.31 to $2.33 per share. This transaction was primarily to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the issuer's equity incentive plan through a "sell to cover" mechanism. This sale does not represent a discretionary trade. Following this transaction, Yoshiyama directly owns 124,517 shares. The filing also notes the inclusion of 3,781 shares acquired by Yoshiyama on March 15, 2026, under an employee stock purchase program.